{"id":"ademetionine-iv-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ademetionine (S-adenosyl methionine, SAMe) is an endogenous compound that serves as the primary methyl donor in the body, facilitating methylation reactions essential for cell membrane integrity, neurotransmitter production, and antioxidant defense. It supports hepatocyte regeneration and reduces hepatic inflammation and fibrosis. The drug is thought to work through multiple pathways including enhancement of glutathione synthesis and modulation of cytokine production.","oneSentence":"Ademetionine is a methyl donor that replenishes cellular methylation capacity and supports hepatic function and neurotransmitter synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:44.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cholestasis and liver disease"},{"name":"Hepatic cirrhosis"},{"name":"Drug-induced liver injury"}]},"trialDetails":[{"nctId":"NCT06258525","phase":"PHASE2","title":"SAMe in Prevention of Oxaliplatin-associated Liver Injury","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-03","conditions":"Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer","enrollment":30},{"nctId":"NCT02200029","phase":"PHASE3","title":"Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption","status":"COMPLETED","sponsor":"Abbott","startDate":"2014-06","conditions":"Intrahepatic Cholestasis Associated With Alcoholic Liver Disease","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ademetionine IV+tablet","genericName":"Ademetionine IV+tablet","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ademetionine is a methyl donor that replenishes cellular methylation capacity and supports hepatic function and neurotransmitter synthesis. Used for Cholestasis and liver disease, Hepatic cirrhosis, Drug-induced liver injury.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}